PolyPid's D-PLEX₁₀₀ Shows Sustained Release in Phase 3 SHIELD II Data
Event summary
- PolyPid to present new Phase 3 SHIELD II data at ESCMID Global 2026 on April 19, 2026.
- D-PLEX₁₀₀ demonstrated detectable doxycycline concentrations for up to 763 hours (32 days).
- Plasma doxycycline levels remained below 100 ng/mL, indicating minimal systemic exposure.
- D-PLEX₁₀₀ received Breakthrough Therapy designation from the FDA for preventing SSIs in colorectal surgery.
The big picture
PolyPid's Phase 3 SHIELD II data reinforces the potential of D-PLEX₁₀₀ to address a critical gap in surgical infection prevention. The sustained local release profile could position it as a key player in reducing SSIs, particularly in colorectal surgeries where infection rates remain high. This aligns with broader industry trends toward targeted, long-acting therapeutics that minimize systemic side effects.
What we're watching
- Regulatory Approval
- Whether the FDA Breakthrough Therapy designation will accelerate D-PLEX₁₀₀'s regulatory pathway.
- Market Adoption
- The pace at which hospitals and surgeons adopt D-PLEX₁₀₀ for colorectal surgeries.
- Competitive Positioning
- How PolyPid differentiates D-PLEX₁₀₀ from existing antibiotic prophylaxis methods.
Related topics